Phoenix Education Partners, Inc. is rated Buy for disciplined, small position sizing, high-risk and regulatory exposure. Read ...
PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback